From: Update on the Treatment of Gastric Cancer
Trial name | Published year |
No. of patients |
Eligible patients | Treatment groups | Morbidity (%) |
5-year OS (%) |
P-value |
---|---|---|---|---|---|---|---|
MRC trial (17), (18) | 1996, 1999 | 737 | cStage I-III | D1 D2 |
28 46 |
35 33 |
0.43 |
Dutch trial (19), (20) | 1995, 2010 | 1078 | cStage I-III | D1 D2 |
25 43 |
45 47 |
0.53 |
Taiwanese trial (21) | 2006 | 335 | cStage I-III | D1 D2 |
7.3 17.1 |
53.6 59.5 |
0.041 |
JCOG9501 (7) | 2008 | 523 | cT3-T4b | D2 alone D2 + PAND |
20.9 28.1 |
69.2 70.3 |
0.85 |
JCOG9502 (8), (9) | 2006, 2015 | 167 | cT2-T4b (cardia/subcardia) |
TH LTA |
34.1 49.4 |
52.3 37.9 |
0.92* |
JCOG0110 (10) | 2017 | 505 | cT2-T4b (proximal) |
Spleen-preservation Splenectomy |
16.7 30.3 |
76.4 75.1 |
0.025* (for non-inferiority) |
JCOG1001 (11) | 2018 | 1204 | cT3-T4a | Omentectomy alone Bursectomy |
10.6 12.8 |
76.7 76.9 |
0.65* |
From: Update on the Treatment of Gastric Cancer
Trial name | Published year |
No. of patients |
Eligible patients |
Treatment groups |
Morbidity (%) |
P-value | Mortality (%) |
P-value |
---|---|---|---|---|---|---|---|---|
JCOG0912 (30) | 2017 | 921 | cStage IA/IB | ODG LDG |
3.7 3.3 |
0.72 | 0 0 |
- |
KLASS-01 (31), (32) | 2015, 2016 | 1416 | cStage IA/IB | ODG LDG |
19.9 13.0 |
0.001 | 0.3 0.6 |
0.450 |
JLSSG0901 (33) | 2017 | 507 | cT2-T4a | ODG LDG |
4.7 3.1 |
0.285 | 0.4 0.4 |
1.000 |
KLASS-02 (34) | 2016 | 1050 | cT2-4a N0-1 | ODG LDG |
24.3 16.4 |
0.002 | 0.6 0.4 |
0.683 |
CLASS-01 (35) | 2018 | 1056 | cT2-T4a | ODG LDG |
15.2 12.9 |
0.285 | 0.4 0 |
0.249 |
From: Update on the Treatment of Gastric Cancer
Trial name | Published year |
No. of patients |
Eligible patients | Treatment groups | Survival (%) |
P-value |
---|---|---|---|---|---|---|
ACTS-GC (39), (40) | 2007, 2011 | 1059 | pStage II-III (D2 gastrectomy) |
no treatment (surgery alone) S-1 |
3-year OS: 70.1 3-year OS: 80.1 |
0.003 |
SAMIT (41) | 2014 | 1495 | cT4a-T4b (D2 gastrectomy) |
UFT with or without paclitaxel S-1 with or without paclitaxel |
3-year DFS: 53.0 3-year DFS: 58.2 |
0.0048 |
CLASSIC (42) | 2014 | 1035 | pStage II-III (D2 gastrectomy) |
no treatment (surgery alone) Capecitabine + oxaliplatin |
3-year DFS: 59 3-year DFS: 74 |
<0.0001 |
OPAS-1 (43) | 2017 | 528 | pStage II | S-1 (6 months) S-1 (12 months) |
3-year RFS: 88.9 3-year RFS: 95.3 |
0.93* (for non-inferiority) |
START-2 (44) | 2018 | 951 | pStage III | S-1 S-1 + docetaxel |
3-year RFS: 49.6 3-year RFS: 65.9 |
0.0007 |
INT-0116 (45) | 2001 | 556 | pStage IB-III (D0/D1 gastrectomy) |
no treatment (surgery alone) 5-FU + LV + RT |
3-year OS: 41 3-year-OS: 50 |
0.005 |
ARTIST (46) | 2015 | 458 | pStage IB-III (D2 gastrectomy) |
Capecitabine + cisplatin Capecitabine + cisplatin + CRT (Capecitabine + RT) |
3-year DFS: 74.2 3-year DFS: 78.2 |
0.0862 |
CRITICS (47) | 2018 | 788 | cStage IB-III (D1+/D2 gastrectomy) |
ECX or EOX ECX or EOX + RT |
5-year OS: 42 5-year OS: 40 |
0.90 |
From: Update on the Treatment of Gastric Cancer
Trial name | Published year |
No. of patients |
Eligible patients |
Treatment groups | R0 resection rate (%) |
OS (%) |
P-value |
---|---|---|---|---|---|---|---|
MAGIC (48) | 2006 | 503 | cStage II-III | Surgery alone ECF (Peri) |
66.4 69.3 |
5-year: 23.0 5-year: 36.3 |
0.009 |
FLOT4 (49), (50) | 2016, 2017 | 716 | cStage IB-III | ECF/ECX (Peri) FLOT (Peri) |
77 84 |
3-year: 48 3-year: 57 |
0.012 |
JCOG0501 (52) | 2018 | 300 | Type 3 (≥8cm) or Type 4 |
CS (Pre) + S-1 (Post) S-1 (Post) |
74.2 65.7 |
3-year: 62.4 3-year: 60.9 |
0.284* |
From: Update on the Treatment of Gastric Cancer
Trial name | Published year |
No. of patients |
Line of treatment |
Treatment groups | Response rate (%) |
MST (months) |
P-value |
---|---|---|---|---|---|---|---|
JCOG9912 (58) | 2009 | 704 | 1st | 5-FU Irinotecan + cisplatin S-1 |
9 38 28 |
10.8 12.3 11.4 |
0.0552* (Irinotecan + cisplatin vs. 5-FU) 0.0005* (for non-inferiority of S-1 vs. 5-FU) |
SPIRITS (59) | 2008 | 298 | 1st | S-1 CS |
31 54 |
11.0 13.0 |
0.04 |
JCOG1013 (60) | 2018 | 741 | 1st | CS DCS |
56.0 59.3 |
15.3 14.2 |
0.47* |
G-SOX (61) | 2015 | 642 | 1st | CS SOX |
52.2 55.7 |
13.1 14.1 |
0.0583 (for non-inferiority) |
REAL-2 (62) | 2008 | 964 | 1st | ECF ECX EOF EOX |
40.7 46.4 42.4 47.9 |
9.9 9.9 9.3 11.2 |
0.02 (ECF vs. EOX) |
ToGA (63) | 2010 | 584 | 1st (HER2-positive) |
Capecitabine/5-FU + cisplatin Capecitabine/5-FU + cisplatin + trastuzumab |
35 47 |
11.1 13.8 |
0.0046 |
RAINFALL (67) | 2018 | 645 | 1st | Capecitabine/5-FU + cisplatin Capecitabine/5-FU + cisplatin + ramucirumab |
36 41 |
10.74 11.17 |
0.68 |
REGARD (65) | 2014 | 355 | 2nd | Placebo Ramucirumab |
3 3 |
3.8 5.2 |
0.047 |
RAINBOW (66) | 2014 | 665 | 2nd | Paclitaxel Paclitaxel + ramucirumab |
16 28 |
7.4 9.6 |
0.017 |
ABSOLUTE (68) | 2017 | 741 | 2nd | weekly paclitaxel (w-Ptx) weekly nab-paclitaxel (w-Nab) triweekly nab-paclitaxel (t-Nab) |
25 24 33 |
10.9 11.1 10.3 |
0.0085* (for non-inferiority of w-Nab vs. w-Ptx) 0.062* (for non-inferiority of t-Nab vs. w-Ptx) |
ATTRACTION-2 (69) | 2017 | 493 | ≥3rd | Placebo Nivolumab |
0 11.2 |
4.14 5.26 |
< 0.0001 |
KEYNOTE-061 (71) | 2018 | 395 | 2nd | Paclitaxel Pembrolizumab |
13.6 15.8 |
8.3 9.1 |
0.042* |